FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

30 results

adcirca
(Tadalafil)
United Therapeutics Corporation
Usage: ADCIRCA® is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise ability, specifically in patients with NYHA Functional Class II-III symptoms, including idiopathic, heritable PAH, and PAH associated with connective tissue diseases.
alyq
(Tadalafil)
Teva Pharmaceuticals Inc
Usage: ALYQ® (tadalafil tablets) is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in patients, particularly those with NYHA Functional Class II-III symptoms, including idiopathic, heritable PAH, and PAH tied to connective tissue diseases.
ambrisentan
(Ambrisentan)
Quallent Pharmaceuticals Health LLC
Usage: Ambrisentan tablets are indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity and delay clinical deterioration. It is primarily studied in patients with WHO Functional Class II–III symptoms, mainly due to idiopathic or heritable PAH or PAH linked to connective tissue diseases.
ambrisentan
(ambrisentan)
Sun Pharmaceutical Industries, Inc.
Usage: Ambrisentan is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity and delay clinical worsening, primarily in patients with WHO Functional Class II–III symptoms and idiopathic, heritable, or connective tissue disease-associated PAH.
bosentan
(Bosentan)
Sun Pharmaceutical Industries, Inc.
Usage: Bosentan is indicated for treating pulmonary arterial hypertension (PAH) in adults to enhance exercise capacity and reduce clinical worsening, particularly in patients with WHO Functional Class II-IV symptoms linked to idiopathic, heritable PAH, connective tissue diseases, or congenital heart disease with left-to-right shunts.
bosentan
(Bosentan)
Zydus Pharmaceuticals USA Inc.
Usage: Bosentan tablets are indicated for treating pulmonary arterial hypertension (PAH) in adults to improve exercise ability and reduce clinical worsening, primarily in patients with WHO Functional Class II-IV symptoms associated with idiopathic, heritable, connective tissue diseases, or congenital heart disease with left-to-right shunts.
bosentan
(bosentan)
Actavis Pharma, Inc.
Usage: Bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) in adults to improve exercise ability and reduce clinical worsening. They are also used in pediatric patients aged 3 and older with idiopathic or congenital PAH to improve pulmonary vascular resistance and exercise ability.
bosentan
(Bosentan)
Amneal Pharmaceuticals LLC
Usage: Bosentan tablets are indicated for treating pulmonary arterial hypertension (PAH) in adults. They improve exercise ability and reduce clinical worsening in patients with WHO Functional Class II-IV symptoms due to idiopathic or heritable PAH, connective tissue diseases, or congenital heart disease with left-to-right shunts.
epoprostenol
(EPOPROSTENOL)
Mylan Institutional LLC
Usage: Epoprostenol for injection is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity, primarily in patients with NYHA Functional Class III-IV symptoms, including those with idiopathic, heritable PAH, or PAH associated with connective tissue diseases.
letairis
(AMBRISENTAN)
Gilead Sciences, Inc
Usage: Letairis is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity, delay clinical worsening, and reduce disease progression and hospitalization risks when combined with tadalafil. It is primarily studied in patients with WHO Functional Class II–III symptoms related to idiopathic, heritable PAH, or connective tissue diseases.

Medications for Pulmonary Arterial Hypertension

adcirca

alyq

ambrisentan

ambrisentan

bosentan

bosentan

bosentan

bosentan

epoprostenol

letairis